123 related articles for article (PubMed ID: 22142830)
1. Targeting the mTOR/4E-BP pathway in endometrial cancer.
Korets SB; Czok S; Blank SV; Curtin JP; Schneider RJ
Clin Cancer Res; 2011 Dec; 17(24):7518-28. PubMed ID: 22142830
[TBL] [Abstract][Full Text] [Related]
2. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
Hidalgo M; Rowinsky EK
Oncogene; 2000 Dec; 19(56):6680-6. PubMed ID: 11426655
[TBL] [Abstract][Full Text] [Related]
3. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
[TBL] [Abstract][Full Text] [Related]
4. [Targeting Ras-PI3K/mTOR pathway and the predictive biomarkers in endometrial cancer].
Oda K
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1084-7. PubMed ID: 21772091
[TBL] [Abstract][Full Text] [Related]
5. New strategies in endometrial cancer: targeting the PI3K/mTOR pathway--the devil is in the details.
Myers AP
Clin Cancer Res; 2013 Oct; 19(19):5264-74. PubMed ID: 24089439
[TBL] [Abstract][Full Text] [Related]
6. Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro.
Darb-Esfahani S; Faggad A; Noske A; Weichert W; Buckendahl AC; Müller B; Budczies J; Röske A; Dietel M; Denkert C
J Cancer Res Clin Oncol; 2009 Jul; 135(7):933-41. PubMed ID: 19107520
[TBL] [Abstract][Full Text] [Related]
7. mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review.
Husseinzadeh N; Husseinzadeh HD
Gynecol Oncol; 2014 May; 133(2):375-81. PubMed ID: 24556063
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia.
Li J; Xue L; Hao H; Han Y; Yang J; Luo J
Oncol Rep; 2012 Feb; 27(2):461-6. PubMed ID: 21993902
[TBL] [Abstract][Full Text] [Related]
9. Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas.
Dobashi Y; Suzuki S; Kimura M; Matsubara H; Tsubochi H; Imoto I; Ooi A
Hum Pathol; 2011 Feb; 42(2):214-26. PubMed ID: 21040950
[TBL] [Abstract][Full Text] [Related]
10. VEGF stimulation enhances Livin protein synthesis through mTOR signaling.
Yan B; Kong M; Chen S; Chen YH
J Cell Biochem; 2010 Dec; 111(5):1114-24. PubMed ID: 20717925
[TBL] [Abstract][Full Text] [Related]
11. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.
Gibbons JJ; Abraham RT; Yu K
Semin Oncol; 2009 Dec; 36 Suppl 3():S3-S17. PubMed ID: 19963098
[TBL] [Abstract][Full Text] [Related]
12. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ
Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679
[TBL] [Abstract][Full Text] [Related]
13. The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling.
van Veelen W; Korsse SE; van de Laar L; Peppelenbosch MP
Oncogene; 2011 May; 30(20):2289-303. PubMed ID: 21258412
[TBL] [Abstract][Full Text] [Related]
14. [mTOR inhibitor].
Muro K
Gan To Kagaku Ryoho; 2011 Jan; 38(1):7-11. PubMed ID: 21368454
[TBL] [Abstract][Full Text] [Related]
15. Cell signaling in endometrial carcinoma: phosphorylated 4E-binding protein-1 expression in endometrial cancer correlates with aggressive tumors and prognosis.
Castellvi J; Garcia A; Ruiz-Marcellan C; Hernández-Losa J; Peg V; Salcedo M; Gil-Moreno A; Ramon y Cajal S
Hum Pathol; 2009 Oct; 40(10):1418-26. PubMed ID: 19428047
[TBL] [Abstract][Full Text] [Related]
16. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies.
Gadducci A; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2006 Jun; 58(3):242-56. PubMed ID: 16436330
[TBL] [Abstract][Full Text] [Related]
17. The rationale for mTOR inhibition in epithelial ovarian cancer.
Trinh XB; van Dam PA; Dirix LY; Vermeulen PB; Tjalma WA
Expert Opin Investig Drugs; 2009 Dec; 18(12):1885-91. PubMed ID: 19888868
[TBL] [Abstract][Full Text] [Related]
18. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
19. Aberrant expression and phosphorylation of 4E-BP1, a main target of mTOR signaling, in rat mammary carcinomas: an association with etiology.
Takabatake M; Daino K; Imaoka T; Nishimura M; Morioka T; Fukushi M; Shimada Y
In Vivo; 2011; 25(6):853-60. PubMed ID: 22021677
[TBL] [Abstract][Full Text] [Related]
20. An expanding role for mTOR in cancer.
Guertin DA; Sabatini DM
Trends Mol Med; 2005 Aug; 11(8):353-61. PubMed ID: 16002336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
